Claris Lifesciences has entered into definitive agreements with Baxter International Inc. (Baxter) for the sale of its global generic injectables business for a total gross consideration of $625 million. The injectables business has been growing rapidly over the last few years and has attracted significant interest. The company intends to repatriate a significant majority of the net cash proceeds (post taxes and expenses) to the shareholders.
Credit Suisse and Jefferies acted as the financial advisers to Claris, Herbert Smith Freehills LLP, Veritas and AZB acted as the legal advisor to Claris.
Claris Lifesciences is a multi-business enterprise and the holding company of Claris Injectables, a wholly- owned subsidiary dealing in Speciality Injectables business and has a minority stake in Claris Otsuka. Claris has a total of 11 approved products in the US, around 25 ANDAs under review with the FDA and markets its products in 75+ countries.
| Company Name | CMP |
|---|---|
| Redington | 220.70 |
| Adani Enterprises | 2300.50 |
| Amrapali Industries | 17.45 |
| Rashi Peripheral | 475.55 |
| PDS | 285.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: